BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 91 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2014. The put-call ratio across all filers is 0.93 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,916,620 | +36.8% | 270,709 | +36.0% | 0.24% | +25.4% |
| Q2 2023 | $1,401,516 | +52.1% | 199,079 | +80.2% | 0.19% | +54.4% |
| Q1 2023 | $921,178 | +31.8% | 110,453 | +81.4% | 0.12% | +10.6% |
| Q4 2022 | $698,902 | -13.5% | 60,880 | -5.1% | 0.11% | -7.4% |
| Q3 2022 | $808,000 | +96.1% | 64,149 | -25.9% | 0.12% | +335.7% |
| Q2 2020 | $412,000 | -42.6% | 86,518 | -33.0% | 0.03% | -3.4% |
| Q2 2017 | $718,000 | -33.8% | 129,200 | 0.0% | 0.03% | -49.1% |
| Q1 2017 | $1,085,000 | +31.0% | 129,200 | -1.2% | 0.06% | +5.6% |
| Q4 2016 | $828,000 | +16.0% | 130,794 | -19.2% | 0.05% | +28.6% |
| Q3 2016 | $714,000 | -36.2% | 161,900 | +116.0% | 0.04% | +44.8% |
| Q2 2015 | $1,119,000 | +62.4% | 74,960 | +6.4% | 0.03% | +61.1% |
| Q3 2014 | $689,000 | -46.3% | 70,474 | -29.9% | 0.02% | -47.1% |
| Q2 2014 | $1,282,000 | +203.1% | 100,514 | +151.4% | 0.03% | +240.0% |
| Q1 2014 | $423,000 | -38.9% | 39,974 | -56.1% | 0.01% | -88.0% |
| Q4 2013 | $692,000 | +179.0% | 91,100 | +167.5% | 0.08% | +1085.7% |
| Q3 2013 | $248,000 | – | 34,057 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 3,926,700 | $56,427,000 | 4.43% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $27,601,000 | 3.44% |
| HealthCor Management, L.P. | 3,849,470 | $55,317,000 | 2.39% |
| MPM BioImpact LLC | 704,767 | $10,128,000 | 1.57% |
| Baker Brothers Advisors | 12,710,818 | $182,654,000 | 0.80% |
| Bain Capital Public Equity Management II, LLC | 1,472,471 | $21,159,000 | 0.74% |
| Biondo Investment Advisors, LLC | 267,480 | $3,844,000 | 0.66% |
| North Star Investment Management Corp. | 442,900 | $6,364,000 | 0.52% |
| DOLIVER ADVISORS, LP | 100,000 | $1,437,000 | 0.48% |
| Lisanti Capital Growth, LLC | 219,450 | $3,153,000 | 0.46% |